Furthermore, it’s not clear whether the strategy to reduce monocyte recruitment in NASH via CCR2/CCL2 inhibition could affect both MoKCs and recruited MoMFs, or the latter cells only. This evidence concerns the gene CCR2 and metabolic dysfunction-associated steatohepatitis.